Safety and Efficacy of Bone Marrow Derived MNCs for Treatment of Cells for the Treatment of Hunting Tons Chorea.

Inclusion Criteria: * Patient should suffer from Hunting tons Chorea, * Hunting tons chorea commonly become noticeable between the ages of 35 -44 * Willingness to undergo Bone Marrow derived Autologous cell Therapy. * Ability to comprehend the explained protocol and thereafter give an informed consent as well as sign the required Informed Consent form(ICF) for the study. * Ability and willingness to regular visit to hospital for protocol procedures and follow up Exclusion Criteria: * Patient with History of Immunodeficiency HIV+,Hepatitis B virus ( HBV) and History of Life threatening allergic or immune -Mediated Reaction. the site of bone marrow aspiration potentially limiting Procedure. * alcohol and drug abuse / dependence. * Severe skin infection. * Haemodynamically unstable. =subject with primary and secondary diabetes , Insulin dependence. * Neurological disease caused by autoimmune or genetic cause. * patients suffering from peripheral muscular dystrophy.